Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 159 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Wasting Clear all
Completed Not applicable Interventional

Spironolactone to Decrease Potassium Wasting in Hypercalciurics on Thiazides Diuretics

NCT00276289
View directory record Official record
Conditions
Idiopathic Hypercalciuria, Hypokalemia Caused by Thiazide Diuretics
Interventions
Spironolactone
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 3 Interventional

Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer

NCT00046904
View directory record Official record
Conditions
Anorexia, Cachexia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
etanercept
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
19
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Jul 21, 2026, 5:26 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effect of Temporal Muscle Suspension of Temporal Hollowing

NCT03324516
View directory record Official record
Conditions
Temporal Wasting
Interventions
Re-Suspension of the temporal muscle after a craniotomy., Traditional re-suspension of the temporal muscle
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

NCT00002127
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Thalidomide
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Greenbrae, California • Redwood City, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 5:26 PM EDT
Active, not recruiting No phase listed Observational

Florida Pancreas Collaborative Next Generation Biobank

NCT03851133
View directory record Official record
Conditions
Pancreatic Cancer, Cancer Cachexia
Interventions
Blood Sample Collection, Tumor Sample collection, Data Collection
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
500 participants
Timeline
2019 – 2027
U.S. locations
14
States / cities
Fort Myers, Florida • Gainesville, Florida • Hialeah, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 21, 2026, 5:26 PM EDT
Recruiting No phase listed Observational

A First-in-Human Study of FID-022 in Solid Tumor Patients

NCT07249775
View directory record Official record
Conditions
Pancreatic Cancer, Cancer Cachexia
Interventions
Baseline Lifestyle and Symptom Assessment, Extended Lifestyle Monitoring, Feasibility Survey
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 21, 2026, 5:26 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin

NCT01262690
View directory record Official record
Conditions
Cachexia
Interventions
PF-05230901
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)

NCT01387282
View directory record Official record
Conditions
Cachexia, Non-Small Cell Lung Cancer
Interventions
Anamorelin HCl, Placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
14
States / cities
Corona, California • Fountain Valley, California • Glendale, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients

NCT01925209
View directory record Official record
Conditions
Sporadic Inclusion Body Myositis
Interventions
BYM338/bimagrumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
36 Years to 85 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 1 Interventional Results available

Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma

NCT00878995
View directory record Official record
Conditions
Cachexia, Squamous Cell Carcinoma
Interventions
Placebo Testosterone, Testosterone Enanthate 100 MG/ML
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

NCT03359473
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Torrance, California • Jacksonville, Florida • High Point, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss

NCT00004912
View directory record Official record
Conditions
Cachexia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
megestrol acetate, physical therapy
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
6
States / cities
North Little Rock, Arkansas • Long Beach, California • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2012 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

NCT00066248
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Jul 21, 2026, 5:26 PM EDT
Terminated No phase listed Observational

Uganda Birth Cohort Study

NCT04233944
View directory record Official record
Conditions
Birth Outcomes, Stunting, Wasting, Anemia
Interventions
Not listed
Lead sponsor
Tufts University
Other
Eligibility
15 Years to 49 Years · Female only
Enrollment
5,044 participants
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

NCT02152761
View directory record Official record
Conditions
Muscle Wasting (Atrophy) After Hip Fracture Surgery
Interventions
bimagrumab, placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Phoenix, Arizona • El Cajon, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Jul 21, 2026, 5:26 PM EDT
Terminated Phase 1 Interventional Results available

Growth Hormone Therapy for Wasting in Cystic Fibrosis

NCT00803179
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nutropin AQ
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 1 Interventional Results available

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

NCT04803305
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Ovarian Cancer, Loss of Appetite, Fatigue, Cachexia, Anorexia
Interventions
PF-06946860, Placebo for PF-06946860
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
32
States / cities
Little Rock, Arkansas • Beverly Hills, California • Camarillo, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Jul 21, 2026, 5:26 PM EDT
Completed No phase listed Observational

Effects of Frailty, Sarcopenia and Muscle Wasting on Outcomes of Patients in the Surgical Intensive Care Unit

NCT02270502
View directory record Official record
Conditions
Critical Illness, Sarcopenia, Muscle Wasting
Interventions
Ultrasound Philips CX50, Frailty Index Questionnaire, Muscle strength tests
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of AV-380 in Healthy Subjects

NCT04815551
View directory record Official record
Conditions
Cachexia
Interventions
AV-380, Placebo
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 1Phase 2 Interventional

Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

NCT01958970
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Disease, Protein Energy Wasting
Interventions
PINTA 745, Placebo
Drug
Lead sponsor
Pinta Biotherapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 1 Interventional

Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia

NCT04131426
View directory record Official record
Conditions
Cachexia; Cancer, Weight Loss, Lung Cancer, Gastrointestinal Cancer
Interventions
Remune, EXCAP©®
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia

NCT00815685
View directory record Official record
Conditions
Cancer Cachexia
Interventions
Eicosapentaenoic Acid
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
25 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Stuart, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Jul 21, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss

NCT00001079
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Testosterone enanthate, Megestrol acetate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 21, 2026, 5:26 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

NCT07083557
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions, Diabetes, Atherosclerotic Disease, Heart Failure, MASH, Sarcopenia, Osteoporosis, Hyperparathyroidism, Hypoparathyroidism, Ischemic Heart Disease, Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Osteopenia, Cachexia
Interventions
Endothelial cell collection
Other
Lead sponsor
Bettina Mittendorfer
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 21, 2026, 5:26 PM EDT